Sugi Predict

Sugi Predict / Compounds / SCHEMBL5962285

SCHEMBL5962285

SCHEMBL5962285

COc1ccc(C(=CC(=O)O)c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.65
▸ CA1 P00915 1/20 0.65
▸ CA2 P00918 1/20 0.65
▸ CA4 P22748 1/20 0.65
▸ CA6 P23280 1/20 0.65
▸ CA7 P43166 1/20 0.65
▸ TPMT P51580 1/20 0.65
▸ CA9 Q16790 1/20 0.65
▸ CA14 Q9ULX7 1/20 0.65
▸ PDE4A P27815 6/20 0.63
▸ PDE4B Q07343 6/20 0.63
▸ PDE4C Q08493 6/20 0.63
▸ PDE4D Q08499 6/20 0.63
▸ TSHR P16473 3/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ CYP2C9 P11712 1/20 0.61
▸ CYP2C19 P33261 1/20 0.61
▸ ALDH1A1 P00352 3/20 0.53
▸ GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9367554 0.98 CA12 (0.62) CA12CA1CA2CA4CA6
SCHEMBL10455031 0.94 PDE4A (0.57) CA12CA1CA2CA4CA6
SCHEMBL10455030 0.94 PDE4A (0.57) CA12CA1CA2CA4CA6
SCHEMBL10385828 0.92 PDE4A (0.56) CA12CA1CA2CA4CA6
SCHEMBL10385830 0.92 PDE4A (0.56) CA12CA1CA2CA4CA6
SCHEMBL8937328 0.92 CTNNB1 (0.57) CA12CA1CA2CA4CA6
SCHEMBL8937325 0.92 CTNNB1 (0.57) CA12CA1CA2CA4CA6
SCHEMBL10385829 0.92 PDE4A (0.56) CA12CA1CA2CA4CA6
SCHEMBL8937502 0.92 PDE4A (0.63) CA12CA1CA2CA4CA6
SCHEMBL8937321 0.92 CTNNB1 (0.57) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019030-B2 Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase CELGENE CORPORATION (US) 2006-03-28 — — US disclosed
US-20040019106-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2004-01-29 — — US disclosed
EP-1361210-A2 Novel immunotherapeutic agents and their use in the reduction of cytokine levels CELGENE CORPORATION (US) 2003-11-12 — — EP disclosed
EP-0918746-B1 IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORP (US) 2003-04-09 — — EP disclosed
US-20030045726-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2003-03-06 — — US disclosed
US-6479554-B2 CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. CELGENE CORPORATION 2002-11-12 — — US disclosed
US-20010056107-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2001-12-27 — — US disclosed
US-6262101-B1 ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE CELGENE CORPORATION 2001-07-17 — — US disclosed
US-6130226-A Immunotherapeutic agents CELGENE CORPORATION (US) 2000-10-10 — — US disclosed
US-5929117-A COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS CELGENE CORPORATION (US) 1999-07-27 — — US disclosed
EP-0918746-A1 IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORPORATION (US) 1999-06-02 — — EP disclosed
WO-1998006692-A1 NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORPORATION (US) 1998-02-19 — — WO disclosed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 — — US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 — — US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 — — EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 — — US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 — — US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045726-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG CA12 3941/4885CA1 3579/4885CA2 2313/4885
US-20040019106-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG CA12 3941/4885CA1 3579/4885CA2 2313/4885
US-20010056107-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG CA12 3941/4885CA1 3579/4885CA2 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.